Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI) Horn, L., Leal, T. A., Oxnard, G., Wakelee, H., Blumenschein, G. R., Waqar, S., Gandhi, L., Chiappori, A. A., Dukart, G., Harrow, K., Liang, C., Tan, F., Gockerman, J. P., Reckamp, K. ELSEVIER SCIENCE INC. 2017: S1556
View details for DOI 10.1016/j.jtho.2017.09.020
View details for Web of Science ID 000461257300019